期刊
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
卷 11, 期 8, 页码 813-827出版社
TAYLOR & FRANCIS AS
DOI: 10.1586/ERM.11.69
关键词
biomarkers; breast cancer; colorectal cancer; expression profiling; immunohistochemistry; in situ hybridization; lung cancer; miRNA; multiplexing; proteins; quantitative reverse-transcriptase polymerase chain reaction
类别
资金
- NIH
- National Cancer Institute [R03 CA141564, R21 CA141017]
The promise of personalized medicine is highly dependent on the identification of biomarkers that inform diagnostic decisions and treatment options, as well as on the accurate, rapid and cost-effective detection and interpretation of these biomarkers. miRNAs, which are short noncoding regulatory RNAs, are rapidly emerging as a novel class of biomarkers with a unique set of biological and chemical properties that makes them very appealing candidates for theranostic applications in cancer. Since the utility of some protein-encoding gene biomarkers is already exploited in routine clinical practice, it will be important to identify areas in which miRNAs provide complementary or superior information to these existing (and other translational) biomarkers to enhance the diagnostic, prognostic and predictive power of molecular characterization of tumors. In this article, the challenges and opportunities for integration of miRNA-based assays in the clinical toolkit to improve care and management of patients afflicted with solid tumors will be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据